Related Experiment Video

Updated: May 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for

Marianne Berg1, Kjetil Soreide

  • 1Department of Surgery, Stavanger University Hospital, Stavanger, Norway.

Discovery Medicine
|October 2, 2012
PubMed

Insights

Targeted therapy for metastatic colorectal cancer (mCRC) shows promise. Identifying predictive biomarkers beyond KRAS is crucial for effective anti-epidermal growth factor receptor (EGFR) treatment selection in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Individualized treatment strategies are advancing, with targeted therapies offering significant benefits for patients with metastatic colorectal cancer (mCRC).
  • Anti-epidermal growth factor receptor (EGFR) therapy has improved outcomes for a subset of mCRC patients, but response prediction remains a challenge.
  • KRAS mutation testing is standard for selecting patients for anti-EGFR therapy, yet many KRAS wildtype patients do not benefit.

Purpose of the Study:

  • To review molecular biomarkers that predict response to anti-EGFR treatment in mCRC.
  • To discuss challenges in patient selection, including other pathway involvement and tumor heterogeneity.

Main Methods:

  • Literature review of molecular biomarkers associated with anti-EGFR therapy response in mCRC.
  • Discussion of genetic pathways (e.g., KRAS-BRAF, PI3K-AKT) and their role in treatment efficacy.
  • Exploration of challenges such as tumor mutation status concordance and acquired resistance.

Main Results:

  • KRAS mutations identify non-responders to anti-EGFR therapy.
  • A significant proportion of KRAS wildtype patients do not respond, indicating the need for additional predictive markers.
  • Other molecular pathways and tumor characteristics influence treatment outcomes.

Conclusions:

  • Predictive biomarker discovery beyond KRAS is essential for optimizing anti-EGFR therapy in mCRC.
  • Understanding molecular mechanisms of response and resistance is key to personalized treatment strategies.
  • Addressing challenges like tumor heterogeneity and treatment-induced mutations will improve patient selection and outcomes.

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...